Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Safety and PK of Oral BT-11 (Omilancor) in Healthy Volunteers
NCT03860571Phase 1Completed
- Sponsor
- NImmune Biopharma
- Start
- Jul 2018
- Primary completion
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in ulcerative colitis (UC) and Crohn's disease comparing Placebo with Omilancor (2 arms). Primary endpoint: Safety and Tolerability at 14 days. Started Jul 2018; status: completed.
02
Drugs
omilancor
03
Conditions
ulcerative colitis (UC)Crohn's disease
Beyond the preview
Go deeper on NCT03860571.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03860571.